French SME providing health economics, pharmacoeconomic modeling, and market access analysis for advanced therapy and drug repurposing research consortia.
FINOVATIS is a Lyon-based health economics consultancy that provides economic modeling, cost-effectiveness analysis, and market access support for clinical research projects. They contribute health economics expertise to EU-funded consortia working on advanced therapies — from stem cell treatments to orphan drug repurposing. Their recurring role across diverse therapeutic areas (stroke, cancer, rare diseases, infectious disease) points to a specialized service profile: they assess the economic viability and reimbursement pathways for experimental treatments moving toward clinical application.
Health economics appears as a keyword across multiple projects (RESSTORE, MCDS-Therapy), and their consistent participant role across diverse therapeutic areas suggests this is their core service offering.
RESSTORE explicitly lists 'in silico' modeling alongside multimodal MRI, and CanPathPro focused on predictive cancer pathway modeling — both requiring computational modeling expertise.
MCDS-Therapy involved repurposing carbamazepine for skeletal dysplasia, requiring economic analysis of orphan drug market access and regulatory pathways.
RESSTORE focused on stem cell therapy for stroke recovery, where FINOVATIS likely assessed cost-effectiveness of allogenic adipose tissue-derived mesenchymal stem cell treatments.
MANCO (2020) on monoclonal antibodies against COVID-19 shows capacity to pivot rapidly to emerging public health needs.
In their earlier H2020 work (2015–2017), FINOVATIS focused on regenerative medicine and computational modeling — contributing health economics and in silico analysis to stem cell therapy (RESSTORE) and cancer pathway prediction (CanPathPro). From 2017 onward, their focus shifted toward rare disease drug repurposing and rapid-response infectious disease work, with MCDS-Therapy addressing orphan drug economics and MANCO tackling COVID-19. The thread connecting all phases is health economics applied to advanced therapies, but the therapeutic targets have diversified significantly.
FINOVATIS is moving from broad therapy evaluation toward niche markets (orphan drugs, repurposed compounds) where health economics input is critical for regulatory and reimbursement decisions.
FINOVATIS operates exclusively as a consortium participant, never as coordinator — consistent with a specialized SME that brings a defined service (health economics) to larger research teams. With 53 unique partners across just 4 projects, they work in large consortia (averaging 13+ partners per project), suggesting comfort with complex multi-country collaborations. Their partner diversity indicates they are a sought-after specialist rather than a group that returns to the same collaborators repeatedly.
FINOVATIS has built a broad European network of 53 unique consortium partners across 12 countries through just 4 projects, indicating they are embedded in large, multi-national clinical research consortia. Their base in Lyon positions them well within the French biomedical research ecosystem.
FINOVATIS fills a specific gap that many clinical research consortia need but few SMEs provide: dedicated health economics analysis for advanced and experimental therapies. Their ability to work across very different therapeutic areas — from stroke recovery to rare bone disorders to pandemic response — shows adaptability without losing their core focus. For consortium builders, they offer a ready-made health economics work package partner with proven experience in RIA projects and multi-partner coordination.
